Form 4: Lemaitre Vascular Director Acquires Additional Dividend Equivalent Rights Tied to Equity Awards
Insider Transaction Report
David B. Roberts, President and Director of Lemaitre Vascular Inc., reported the acquisition of additional dividend equivalent rights linked to his existing restricted stock and performance share unit awards.
Summary
- David B. Roberts, President and Director of Lemaitre Vascular Inc. (LMAT), filed a Form 4 reporting changes in his beneficial ownership of derivative securities.
- On May 29, 2025, Mr. Roberts acquired a total of 22.1927 Dividend Equivalent Rights (DERs) across eight separate transactions.
- These DERs accrued on various restricted stock unit (RSU) and performance share unit (PSU) awards previously granted to Mr. Roberts between December 2, 2020, and February 18, 2025.
- Each Dividend Equivalent Right is the economic equivalent of one share of Lemaitre Vascular's common stock and vests proportionately with its underlying RSU or PSU award.
- Following these transactions, Mr. Roberts' total beneficial ownership of these specific Dividend Equivalent Rights across all reported awards is 156.2178.
- The acquisition price for these DERs was $0, as they represent accruals on existing equity awards rather than direct purchases.
Sentiment
Score: 7
Explanation: The filing is neutral to slightly positive, as it indicates the ongoing operation of executive compensation plans and aligns management's interests with shareholders through equity awards. It is a routine disclosure with no negative implications.
Positives
- The accrual of Dividend Equivalent Rights indicates the continued vesting of previously granted equity awards, which aligns the interests of management with those of shareholders.
- This filing reflects a routine aspect of executive compensation, demonstrating the ongoing commitment of a key executive to the company's long-term performance.
Future Outlook
The document does not provide forward-looking statements regarding the company's financial performance or strategic direction, but it implies the continued vesting of the underlying restricted stock units and performance share units to which these dividend equivalent rights are tied.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction related to executive compensation. It reflects standard practices for equity-based incentive programs within publicly traded companies, particularly those in the medical device or healthcare sector like Lemaitre Vascular.
Related Party Transactions
- The acquisition of Dividend Equivalent Rights by a director and officer (David B. Roberts) is a form of executive compensation, which is a common type of related party transaction designed to incentivize and retain key personnel.
Stakeholder Impact
- Shareholders: The accrual of these rights aligns the interests of a key executive with shareholders, as the value of these rights is tied to the company's common stock performance and dividend policy.
- Employees: This reflects standard executive compensation practices, which can influence overall compensation structures within the company.
Next Steps
- Continued vesting of the underlying Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards, to which these Dividend Equivalent Rights are proportionately tied.
Key Dates
| Date | Description |
|---|---|
| 12/02/2020 | Grant date of a restricted stock unit award on which dividend equivalent rights accrued. |
| 12/11/2021 | Grant date of a restricted stock unit award on which dividend equivalent rights accrued. |
| 12/12/2022 | Grant date of a restricted stock unit award and a Performance Share Unit (PSU) award on which dividend equivalent rights accrued. |
| 12/08/2023 | Grant date of a restricted stock unit award and a Performance Share Unit (PSU) award on which dividend equivalent rights accrued. |
| 12/06/2024 | Grant date of a restricted stock unit award on which dividend equivalent rights accrued. |
| 02/18/2025 | Grant date of a restricted stock unit award on which dividend equivalent rights accrued. |
| 05/29/2025 | Transaction date for the acquisition of Dividend Equivalent Rights. |
| 06/02/2025 | Date the Form 4 filing was signed. |
Keywords
Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.